8-K filing — Ocugen, Inc. (OCGN)
Filed: 2026-08-06 AccNo: 0001104659-26-091691 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Ocugen Announces First Patient Dosed In Global Phase 3 Registrational Trial Of OCU410, Modifier Gene Therapy Candidate For GA Secondary To Dry Age-Related Macular Degeneration
The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine Advanced Therapy
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 40 percent decrease over losses of $(0.05) per share from the same
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration